Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.95
- Piotroski Score 1.00
- Grade N/A
- Symbol (QTTB)
- Company Q32 Bio Inc.
- Price $31.32
- Changes Percentage (-4.93%)
- Change -$1.63
- Day Low $30.86
- Day High $33.88
- Year High $53.79
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/07/2025
- Fiscal Year End N/A
- Average Stock Price Target $54.00
- High Stock Price Target $95.00
- Low Stock Price Target $45.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio N/A
- Forward P/E Ratio N/A
- P/E Growth N/A
- Net Income $-112,961,000
Income Statement
Quarterly
Annual
Latest News of QTTB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake
Q32 Bio Inc. has 4 major investors holding a majority stake of 52%. Private equity firms dominate the ownership, but hedge funds have minimal shares. Insider ownership is low, with the general public ...
By Yahoo! Finance | 4 months ago
